Luka Kovacevic

Luka Kovacevic

Auto-generated profile, based on publicly available information

Luka Kovacevic

MRC Biostatistics Unit, East Forvie Building, Forvie Site, Robinson Way, Cambridge Biomedical Campus, Cambridge CB2 0SR

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2023 in Regenerative Medicine
Verified
Journal Article
Closed access
PRPredrag Rasovic
Predrag Rasovic
ODOliver Dulic
Oliver Dulic
LILalić Ivica
Lalić Ivica
RMRadmila Matijevic
Radmila Matijevic
NJNatasa Janjic
Natasa Janjic
LKLuka Kovacevic
Luka Kovacevic
Aim: The aim of this study was to assess whether BMI, severity of knee osteoarthritis, age and gender have any influence on the final clinical results of bone marrow aspirate concentrate injection....

31 December 2024 in Biostatistics
Verified
Journal Article
Open access
LKLuka Kovačević
Luka Kovačević
WCWeishi Chen
Weishi Chen
HBHelen Barnett
Helen Barnett
TJThomas Jaki
Thomas Jaki
PMPavel Mozgunov
Pavel Mozgunov
Summary: Phase I clinical trials are essential to bringing novel therapies from chemical development to widespread use. Traditional approaches to dose-finding in Phase I trials, such as the ‘3 + 3’ method and the continual reassessment method (CRM), provide a principled approach for escalating across dose levels. However, these methods lack the ability to incorporate uncertainty regarding the dose-toxicity ordering as found in combination drug trials. Under this setting, dose levels vary across multiple drugs simultaneously, leading to multiple possible dose-toxicity orderings. The CRM for partial ordering (POCRM) extends to these settings by allowing for multiple dose-toxicity orderings. In this work, it is shown that the POCRM is vulnerable to ‘estimation incoherency’ whereby toxicity estimates shift in an illogical way, threatening patient safety and undermining clinician trust in dose-finding models. To this end, the Bayesian model averaged POCRM (BMA-POCRM) is formalized. BMA-POCRM uses Bayesian model averaging to take into account all possible orderings simultaneously, reducing the frequency of estimation incoherencies. We derive novel theoretical guarantees on the estimation coherency of the POCRM and BMA-POCRM. The effectiveness of BMA-POCRM in drug combination settings is demonstrated through a specific instance of estimate incoherency of POCRM and simulation studies. The results highlight the improved safety, accuracy, and reduced occurrence of estimate incoherency in trials applying the BMA-POCRM relative to the POCRM model.